| Species |
Human |
| Protein Construction |
| His |
Latent TGF beta 3/TGFB3 (Leu24-Ser412)_x000D_
Accession # P10600-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Latent TGF beta 3, His, Human at 2μg/ml (100μl/well) on the plate can bind Human TGFbeta RII, mFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
45.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 46-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Transforming growth factor-betas (TGF-βs) are multifunctional cytokines that have been implicated in the regulation of a broad range of biological processes, including cell proliferation, cell survival, and cell differentiation. And transforming growth factor beta3 (TGFbeta3) is a key protein involved in scar-free healing observed in embryos. |
| Synonyms |
TGFB3; ARVD; TGF-beta3; TGF-β; TGFβ3; TGFβ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
